RxDoctor Payments Data

Hector Lopez Marquez, MD

Pain Medicine · North Dartmouth, MANPI 1215469861

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (43.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.2%.

$10,102in general payments, 2019–2025

Across 144 payments — averaging $70.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$2K
  • Boston Scientific$1K
  • Stryker$1K
  • Medtronic$1K
  • Relievant Medsystems, Inc.$878
  • Spinal Simplicity, LLC$740
  • plus $3K from 17 others

What the payments were for

  • Speaking & faculty fees$1,64516%
  • Travel & lodging$4,34543%
  • Food & beverage$4,11341%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,102 in reported general payments places this provider in the 85th percentile of 137 pain medicine providers in Massachusetts.

See all pain medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$179,291
Medicare patients
450
Services billed
2,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl19$13,683
Xtampza ErOxycodone Myristate22$10,742
Buprenorphine60$9,590
Pregabalin207$8,489
BelbucaBuprenorphine Hcl12$7,023
SavellaMilnacipran Hcl12$5,888
Celecoxib167$4,870
Gabapentin376$4,182
Fentanyl28$3,394
Oxycodone Hcl294$3,321
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen207$2,742
Lidocaine26$2,442
Morphine Sulfate ErMorphine Sulfate109$1,936
Duloxetine Hcl152$1,583
Baclofen92$1,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSavella$503$5,88812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 137 pain medicine providers in Massachusetts.

Other pain medicine in North Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →